WebOct 19, 2024 · Foghorn Therapeutics, a preclinical biotech developing gene therapies for hematologic cancers and solid tumors, announced terms for its IPO on Monday. The … WebIn October 2024, an IPO was completed raising $120 M for an initial market cap of ~$570 M. Management Much of the management is linked to big pharma, Agios and Flagship. Below are some of the key individuals. The President & CEO is Adrian Gottschalk, former SVP Therapeutic Area Head for Neurodegeneration at Biogen.
Foghorn Booms onto Nasdaq with $120M IPO
WebApr 10, 2024 · Foghorn Therapeutics Inc. ha annunciato che i dati preclinici di due dei suoi programmi di degradazione proteica, Selective EP300 e Selective CBP, e i dati preclinici per il suo inibitore BRG1/BRM,... 12 aprile 2024 WebFoghorn Therapeutics Inc. Financial Information: Market Cap: $571.04mil: Revenues: $0 mil (last 12 months) Net Income $-58.1 mil (last 12 months) IPO Profile: Symbol: FHTX: … chiefs super bowl 2023 shirt
Foghorn Therapeutics Rings the Opening Bell in Celebration of its IPO
WebOct 5, 2024 · Preclinical biotech Foghorn Therapeutics is aiming for a $100 million IPO, but don’t be surprised it if goes the way of many other biotech listings and shoots far north of that. WebNov 14, 2024 · US IPO market activity is picking back up ahead of the Thanksgiving holiday, with six IPOs scheduled to raise $3.4 billion in the week ahead. Biotech research product provider Maravai LifeSciences plans to raise $1.3 billion at a $6.6 billion market cap. ... Foghorn Therapeutics; News; U.S. IPO Week Ahead: 6 IPOs Squeeze In Before The ... WebApr 10, 2024 · Foghorn Therapeutics Inc. FHTX, another stock in the same industry, closed the last trading session 1.2% higher at $5.86. FHTX has returned 5.9% in the past month. Foghorn Therapeutics... gotfootball admin login